VALacyclovir In Delaying Antiretroviral Treatment Entry.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Feb 2017
At a glance
- Drugs Valaciclovir (Primary)
- Indications Herpes simplex virus type 2 infections; HIV infections; HIV-1 infections
- Focus Biomarker; Therapeutic Use
- Acronyms VALIDATE
- 07 Jun 2017 Biomarkers information updated
- 16 Feb 2017 Primary endpoint (Annual rate of change in CD4 count, calculated as the slope of participants CD4 count change / time.) has not been met.
- 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections